AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04694443 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard in-office medical care
Description: Non-pharmacological and pharmacological treatment provided in-office visits
Study NCT03816696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3640254
Description: GSK3640254 will be available as 100 mg capsules. Subjects will be administered GSK3640254 200 mg QD via the oral route.
Study NCT03816696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG
Description: DTG will be available as 50 mg tablets. Subjects will be administered DTG 50 mg QD via the oral route.
Study NCT00617734 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-A12 (cixutumumab)
Description: IMC-A12 10 milligrams per kilogram (mg/kg) over one hour every two weeks. A cycle is defined as four weeks of therapy. Participants will continue on study until evidence of progressive disease, or unacceptable toxicity develops.
Study NCT00617734 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab (Erbitux ®)
Description: IMC-A12 10 mg/kg over one hour followed by cetuximab 500 milligrams per square meter (mg/m\^2) over two hours. This sequence will be repeated every two weeks. Participants will continue on study until evidence of progressive disease or unacceptable toxicity develops.
Study NCT01004952 — intervention group
Intervention type: BEHAVIORAL
Intervention: screening questionnaire
Description: Phase I involves in-home interviews of 25 participants to understand the factors that affect participants' decision-making about UVR protection (sunscreen use, shade-seeking, hat use, use of protective clothing). In Phase II, we plan to recruit a sample of 60 melanoma first degree relatives (FDRs) and use an electronic narrative diary to record their daily behaviors about UVR protection. They will be asked to carry a interactive voice response (IVR) system for 14 days and they should be in the continental United States.
Study NCT04503070 — intervention group
Intervention type: BEHAVIORAL
Intervention: Motion capture participant
Description: Once participants have undergone appropriate calibration processes, they will perform listed swing progressions:~1. 15 dry swings with a wiffle bat at low, medium and high effort~2. 15 dry swings with a weighted bat at low, medium and high effort~3. 15 swings off of a tee at low, medium and high effort~4. 15 swings at an underhand toss at low, medium and high effort~5. 15 swings from a pitching machine at low, medium and high effort
Study NCT01648712 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Balance surface, Carmeda heparin-coated surface
Description: This study compares the influence of a Balance - coated CPB system in pediatric use versus the Carmeda TM heparin-coated system in platelet function preservation and hemostatic activation.~Balance arm group recieved like intervention a Balance circuit
Study NCT01648712 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: non -heparin extracorporeal pediatric device for operation
Description: The carmeda arm group received like intervention the Carmeda circuit
Study NCT03694561 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: This study is a systematic investigation of the natural history of late-onset Pompe disease in infancy and childhood
Study NCT01943643 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: multislice CT angiography
Description: Study patients will undergo MSCTA on Toshiba Aquilion CXL 128 slice CT scanner using predefined protocol. The procedure will include calcium scoring (Agatston) then CT angiography using Ultravist 370 contrast agent ((iopromide concentration 370 mg/ml, Bayer Health Care, Germany). MSCTA angiograms will be analyzed using dedicated software Vital Vitrea Advanced 6.2, Vital Images, Minnetonka, Minnesota, US. The bifurcation lesion analyses will include: the measurement of the angle between MB and SB, measurement of the lesion length, reference diameter of the vessel, degree of stenosis, atherosclerotic plaque analysis 10 mm proximal and distal in the MB, and 5 mm from the ostium of the SB, and at the level of maximum stenosis (minimal lumen diameter).
Study NCT01847521 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Luteolin, Quercetin and Rutin combined in a capsule
Study NCT02488577 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transanal minimally invasive total mesorectal excision
Study NCT02488577 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transanal minimally invasive locoregional resection
Study NCT01402752 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood flow to the tracheo-bronchial mucosa
Description: Measurement of blood flow to the tracheo-bronchial mucosa via differential absorption of diluted dimethyl ether tracer gas.
Study NCT04041713 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rett-T
Description: antioxidant cocktail
Study NCT04041713 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03107481 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Acetaminophen 1g IV
Study NCT03107481 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydromorphone
Description: Hydromorphone 1mg IV
Study NCT00647517 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ultracet
Description: For the treatment arm: Tramadol 37.5 mg/APAP 325 mg combination tablets (Ultracet®) one tablet twice a day plus aceclofenac tablet per oral 100 mg twice a day.~For the control group: Placebo plus aceclofenac tablet per oral 100 mg twice a day.
Study NCT00647517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ultracet
Description: For the treatment arm: Tramadol 37.5 mg/APAP 325 mg combination tablets (Ultracet®) one tablet twice a day plus aceclofenac tablet per oral 100 mg twice a day.~For the control group: Placebo plus aceclofenac tablet per oral 100 mg twice a day.
Study NCT03660462 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: FeSO4 fortified rice test meal
Description: Rice test meal extrinsically labeled with 2 mg ferrous sulfate (58FeSO4)
Study NCT03660462 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: FePO4 fortified rice test meal
Description: Rice test meal extrinsically labeled with 2 mg ferric phosphate (58FePO4)
Study NCT03660462 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HiFePO4 1 fortified rice test meal
Description: Rice test meal extrinsically labeled with 2 mg high surface ferric phosphate 1 (57FePO4)
Study NCT03660462 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HiFePO4 2 fortified rice test meal
Description: Rice test meal extrinsically labeled with 2 mg high surface ferric phosphate 2 (57FePO4)
Study NCT03201068 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic supplement
Description: Probiotic supplement capsule
Study NCT03201068 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule
Study NCT03064529 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accelerometer
Description: All participants receive a wrist worn accelerometer to measure physical activity continuously before and after surgery
Study NCT02173080 — intervention group
Intervention type: OTHER
Intervention: PLD-Q
Description: polycystic liver disease questionnaire
Study NCT03804528 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Participants will be fitted with a heart rate monitor and will be instructed to walk (or trot) to maintain 55-64% of maximal heart rate (determined by exercise test) for the first 4-weeks of exercise or to maintain 65-90% of maximal heart rate (determined by exercise test) for the second 4-weeks of exercise during each session. Participants are provided the option to participate remotely due to COVID-19 pandemic, as detailed below. Both options are designed to be equivalent in intervention and outcome measures.~Option A: Current, IRB-approved, in-person methods pending appropriateness based on current University of Miami recommendations and standard operating procedures as it relates to the COVID-19 pandemic.~Option B: Remote option of current methods to maximize recruitment. This will be the only option until the study team obtains approval to resume Option A (as per University's safety guidelines).
Study NCT03433651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate
Description: Subjects will take by mouth 5 grams a day of creatine monohydrate powder.
Study NCT03433651 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will take by mouth 5 grams a day of placebo powder.
Study NCT01568177 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mental Stress Testing
Description: Mental stress testing is used to test the mechanistic pathways through which biobehavioral variables are involved in the pathogenesis of MCD in women.
Study NCT01568177 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Peripheral Arterial Tonometry (PAT) Testing
Description: PAT measurements will be used to predict ischemia in patients with MCD. PAT will be measured by Endo PAT 2000 (Itamar® Medical Ltd).
Study NCT01568177 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Heart Rate Variability (HRV)
Description: Holter monitor will be used to measure heart rate and rhythm for approximately 24 hours.
Study NCT01568177 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: RESPeRATE Breathing Trial
Description: RESPeRATE Breathing will test whether a controlled breathing relaxation technique using an FDA-approved paced breathing device, RESPeRATE, helps with chest pain and shortness of breath and will test to see if this form of biofeedback or relaxation technique helps with heart rate variability during mental stress.
Study NCT01568177 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: SPECT cardiac scan with 123I-mIBG and Myoview
Description: Single Photon Emission Computed Tomography (SPECT) cardiac scan with 123I-mIBG and Myoview will be used to measure cardiac sympathetic activity.
Study NCT04049032 — intervention group
Intervention type: BEHAVIORAL
Intervention: In-Person Perinatal OUD Treatment
Description: Participants were seen weekly for four weeks, every two weeks for four weeks and monthly thereafter and provided relapse-prevention therapy and buprenorphine as part of standard of care.
Study NCT04049032 — intervention group
Intervention type: BEHAVIORAL
Intervention: Perinatal OUD Treatment via Telemedicine
Description: Participants were seen weekly for four weeks, every two weeks for four weeks and monthly thereafter and provided relapse-prevention therapy and buprenorphine as part of standard of care..
Study NCT04500158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: 2% Lidocaine with 1:100,000 epi
Study NCT03064802 — intervention group
Intervention type: DEVICE
Intervention: BioBurst Fluid, Burst Allograft
Description: BioBurst Fluid or Burst Allograft used to augment spinal fusion
Study NCT03396809 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Punctal plug
Description: Punctal plugs are FDA approved for the treatment of dry eye. They increase lubrication of the eye by blocking the drainage of tears into the lacrimal sac. The nose portion of the plug has a larger diameter which is designed to fit in the canaliculum in order to retain the plug in the punctum. The plugs will be used on-label, as it is FDA approved in the treatment of dry eye. The purpose of punctal plugs are to increase tear volume by preventing drainage of tears into the lacrimal sac. The plugs are removable if necessary. Investigators are not testing this device for effectiveness or safety.
Study NCT01049295 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: oil fish
Description: Active Comparator:640 mg oral oil fish pearls( 54% DHA, 10% EPA) 3 times a day
Study NCT01049295 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: corn oil pearls
Description: corn oil pearls 3 times a day
Study NCT01415531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebivolol
Description: Nebivolol (non-trade 5, 10 or 20 mg tablet), oral administration
Study NCT02008396 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive capsules of lactose of identical appearance to MDMA capsules during each of two experimental sessions. Capsules will be administered along with therapy.
Study NCT02008396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midomafetamine HCl
Description: Participants in Group 1 receive 75 or 100 mg during the two experimental sessions and participants in Group 2 receive 100 or 125 mg during two experimental sessions.
Study NCT02008396 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapy
Description: Therapy conducted throughout experimental sessions. Therapists will use a largely nondirective approach. There will be periods of structured and unstructured interactions. The structured interactions will be selected based on elements of therapeutic interventions that are currently in use in this population for the treatment of social anxiety.
Study NCT02008396 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Therapy
Description: Therapy conducted throughout experimental sessions. Therapists will use a largely nondirective approach. There will be periods of structured and unstructured interactions. The structured interactions will be selected based on elements of therapeutic interventions that are currently in use in this population for the treatment of social anxiety.
Study NCT06700668 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MIT Powered Knee
Description: MIT powered knee prosthesis developed by the MIT Biomechatronics Group.
Study NCT06704438 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: D-Lactate
Description: D-Lactate and SCUBE-1 can be used as early diagnosis and mortality indicators in critically ill patients.
Study NCT01415531 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dose-match placebo
Study NCT06705608 — intervention group
Intervention type: DRUG
Intervention: Fingolimod
Description: patients who received fingolimod for treating RRMS
Study NCT06705608 — intervention group
Intervention type: DRUG
Intervention: Natalizumab
Description: patients who received natalizumab for treating RRMS (active comparator)
Study NCT06705608 — intervention group
Intervention type: DRUG
Intervention: Dimethyl fumarate (DMF)
Description: patients who received dimethyl fumarate for treating RRMS (active comparator)
Study NCT06705608 — intervention group
Intervention type: DRUG
Intervention: Alemtuzumab
Description: patients who received alemtuzumab for treating RRMS (active comparator)
Study NCT06705608 — intervention group
Intervention type: DRUG
Intervention: Teriflunomide
Description: patients who received teriflunomide for treating RRMS (active comparator)
Study NCT02633059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO
Study NCT02633059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idasanutlin
Description: Given PO
Study NCT02633059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib Citrate
Description: Given PO
Study NCT02633059 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02633059 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT00684866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levalbuterol HFA MDI followed by Racemic albuterol HFA MDI
Description: (a) Subjects will receive both treatments: (a) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses); followed by (b) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses)
Study NCT00684866 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Racemic Albuterol followed by levalbuterol HFA MDI
Description: (a) Subjects will receive both treatments: (a) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses) followed by (b) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses)
Study NCT04449913 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 10 days intensive meditation retreat
Description: The intervention consists in a 10 days contemplative retreat, with 6 to 8 hours of sitting and walking meditation per day, and 1 or 2 hours of meditation teachings. The meditation practice will mainly train in mindfulness practice. Mindfulness meditation intends to train attention to detect and regulate afflictive cognitive and emotional patterns. Mindfulness practice requires skills involved in openness to experience, in monitoring the focus of attention and in detecting distraction, disengaging attention from the source of distraction, and flexibly (re)directing and engaging attention to the intended object. A brief introduction to loving-kindness and compassion meditation will also be present throughout the retreat.
Study NCT04449913 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Waiting for a 10 days intensive meditation retreat
Description: At the time of measure, participants in this group are waiting to participate to the same meditation retreat as the active group. They may perform their own daily meditation practices as usual.
Study NCT02539823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD 400 mg
Description: Subjects in Arm CBD 400 mg will receive 400mg of Cannabidiol in each of the three test sessions
Study NCT02539823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD 800 mg
Description: Subjects in Arm CBD 800 mg will receive 800mg of Cannabidiol in each of the three test sessions
Study NCT02539823 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control (placebo)
Description: Subjects will receive a harmless, inactive solution to compare and validate the results of the other arms of the study
Study NCT02191462 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Niagen 100mg
Study NCT02191462 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Niagen 300mg
Study NCT02191462 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Niagen 1000mg
Study NCT01962792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Study NCT01962792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Study NCT01962792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study NCT01733420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biodentine pulpotomy
Study NCT01733420 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: White MTA pulpotomy
Study NCT01733420 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tempophore pulpotomy
Study NCT01198886 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Successful Aging Program
Description: Once per week discussion on lifestyle topics important to older adults. Classes conclude with a gentle upper body stretching routine.
Study NCT01198886 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise-Nutrition Program
Description: Targeted exercise program offered 3-days per week at the study participants place of residence (senior housing facility). Other means to encourage physical activity outside of these exercise classes will be available. A nutrient-rich protein carbohydrate experimental beverage will be taken following the exercise sessions.
Study NCT03449511 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ginger aromatherapy
Description: Three sniffs of aromatherapy inhaler four times daily for seven days.
Study NCT03449511 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Orange aromatherapy
Description: Three sniffs of aromatherapy inhaler four times daily for seven days.
Study NCT03449511 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lavender aromatherapy
Description: Three sniffs of aromatherapy inhaler four times daily for seven days.
Study NCT03449511 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Jojoba aromatherapy
Description: Three sniffs of aromatherapy inhaler four times daily for seven days.
Study NCT04590274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine
Study NCT04590274 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamins and Minerals
Description: elemental Zinc Vitamin C Vitamin D3 N-acetylcysteine Elderberry Quercetin
Study NCT04590274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Azithromycin
Study NCT00383786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NK1 Antagoist (GR205171)
Study NCT00383786 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Psychophysiology (Trauma Script)
Study NCT00383786 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Psychophysiology (Trauma Script)
Study NCT00383786 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Psychophysiology (Verbal Threat)
Study NCT00383786 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Psychophysiology (Verbal Threat)
Study NCT00383786 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Psychophysiology (Fear Conditioning)
Study NCT00383786 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Psychophysiology (Fear Conditioning)
Study NCT00383786 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Psychophysiology (Affective Modulation)